Autopsy report · NCT02933801

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

“Decision Board no further financial support after 3 years of follow-up as remaining patients in follow-up phase would not relevantly change the endpoints.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 6 years 7 months before it stopped.
• 92 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Swiss Cancer Institute

Sponsor type

University, hospital or other

Conditions

Prostate Cancer Metastatic; Prostate Cancer

Interventions

ODM-201; Placebo

Participants

92

Sites

32

Countries

France, Italy, Spain, Switzerland

Trials that died the same way

• Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
  “The study team decided to not move forward with enrolling patients because funding was not identified to support the project.” (60% match in meaning)
• Pharmacodynamics of Nasal and Buccal Midazolam Using EEG
  “Funding agency no longer provide support.” (59% match in meaning)
• CharactHer. ICORG 12-09, V3
  “As per the HRBs new funding model, HRBs investment will not support costs associated with routine patient care or translational studies, biobanks, patient registries and questionnaires. Therefore, a decision was made to cease further study follow up.” (59% match in meaning)
• Goal Attainment and Physical Activity in People With Hemophilia A
  “Early discontinuation based on sponsor decision not driven by any safety concerns.” (58% match in meaning)
• Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function
  “It was not possible within the time frame to recruit the planned no. of patients.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.